Andrew Skingsley

1.1k total citations · 1 hit paper
25 papers, 592 citations indexed

About

Andrew Skingsley is a scholar working on Infectious Diseases, Epidemiology and Emergency Medicine. According to data from OpenAlex, Andrew Skingsley has authored 25 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 6 papers in Epidemiology and 5 papers in Emergency Medicine. Recurrent topics in Andrew Skingsley's work include HIV/AIDS drug development and treatment (9 papers), HIV/AIDS Research and Interventions (8 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Andrew Skingsley is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV/AIDS Research and Interventions (8 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Andrew Skingsley collaborates with scholars based in United Kingdom, United States and Canada. Andrew Skingsley's co-authors include Valérie Delpech, Sara Croxford, Sarika Desai, Fiona Burns, Andrew Copas, Alison Brown, A. Kitching, Michael Edelstein, Ann Sullivan and Meaghan Kall and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Andrew Skingsley

22 papers receiving 584 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort

2016 273 citations Sara Croxford, A. Kitching et al. The Lancet Public Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Skingsley United Kingdom	9	355	229	159	149	49	25	592
Selvamuthu Poongulali India	14	462 1.3×	206 0.9×	127 0.8×	217 1.5×	32 0.7×	46	696
Annette Haberl Germany	18	499 1.4×	310 1.4×	154 1.0×	285 1.9×	41 0.8×	56	868
Catherine Capitant France	14	419 1.2×	299 1.3×	87 0.5×	312 2.1×	18 0.4×	31	786
Barbara Bertisch Switzerland	12	434 1.2×	461 2.0×	398 2.5×	165 1.1×	13 0.3×	29	856
Melissa R. Pfeiffer United States	11	340 1.0×	240 1.0×	236 1.5×	116 0.8×	68 1.4×	15	680
Jessica L. Castilho United States	15	502 1.4×	253 1.1×	369 2.3×	219 1.5×	29 0.6×	39	768
Bernardino Roca Spain	14	232 0.7×	153 0.7×	55 0.3×	86 0.6×	9 0.2×	54	507
Maria Letícia Rodrigues Ikeda Brazil	12	211 0.6×	110 0.5×	212 1.3×	82 0.6×	36 0.7×	27	408
Marc Delforge Belgium	14	207 0.6×	235 1.0×	73 0.5×	81 0.5×	11 0.2×	45	515
A. Loy Italy	11	272 0.8×	150 0.7×	117 0.7×	183 1.2×	56 1.1×	21	584

Countries citing papers authored by Andrew Skingsley

Since Specialization

Citations

This map shows the geographic impact of Andrew Skingsley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Skingsley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Skingsley more than expected).

Fields of papers citing papers by Andrew Skingsley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Skingsley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Skingsley. The network helps show where Andrew Skingsley may publish in the future.

Co-authorship network of co-authors of Andrew Skingsley

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Skingsley. A scholar is included among the top collaborators of Andrew Skingsley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Skingsley. Andrew Skingsley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moore, Jennifer, et al.. (2025). Safety and tolerability of intramuscular sotrovimab administered at different injection sites: results from the Phase 1 COSMIC study. mAbs. 17(1). 2456467–2456467.

Sager, Jennifer E., Sergio Parra, Jennifer Moore, et al.. (2024). Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. 117(3). 759–767.

Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2024). Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab. Future Virology. 19(5). 185–198.

Alexander, Elizabeth, Stephen A. Harrison, Marjan Hezareh, et al.. (2023). Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers. Clinical Pharmacokinetics. 63(1). 57–68. 2 indexed citations

Sager, Jennifer E., Julie Passarell, Xiaobin Li, et al.. (2023). Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19. CPT Pharmacometrics & Systems Pharmacology. 12(6). 853–864. 5 indexed citations

Gibbons, Daniel C., et al.. (2023). Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review. Infection. 52(1). 1–17. 7 indexed citations

Moya, Jaynier, Sergio Parra, Erick Stanley Petersen Juárez, et al.. (2023). Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial. Open Forum Infectious Diseases. 10(7). ofad344–ofad344. 2 indexed citations

Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2022). 1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab. Open Forum Infectious Diseases. 9(Supplement_2). 3 indexed citations

Croxford, Sara, Zheng Yin, Fiona Burns, et al.. (2018). Linkage to HIV care following diagnosis in the WHO European Region: A systematic review and meta-analysis, 2006-2017. PLoS ONE. 13(2). e0192403–e0192403. 28 indexed citations

10.

Winter, Joanne R., Helen R. Stagg, Colette Smith, et al.. (2017). Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV. AIDS. 31(17). 2403–2413. 6 indexed citations

11.

Croxford, Sara, A. Kitching, Sarika Desai, et al.. (2016). Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. The Lancet Public Health. 2(1). e35–e46. 273 indexed citations breakdown →

12.

Skingsley, Andrew, Simbarashe Takuva, Alison Brown, Valérie Delpech, & Adrian Puren. (2015). Monitoring HIV-Related Mortality in South Africa: The challenges and urgency. 2 indexed citations

13.

Trinidade, Aaron, et al.. (2014). Pediatric Cholesteatoma Surgery Using a Single-Staged Canal Wall Down Approach. Otology & Neurotology. 36(1). 82–85. 29 indexed citations

14.

Ramagopalan, Sreeram V, Andrew Skingsley, Lahiru Handunnetthi, et al.. (2014). Data set of primary outcome changes in interventional clinical trials registered on ClinicalTrials.org. London School of Hygiene & Tropical Medicine. 1 indexed citations

15.

Lessells, Richard, Katharine E. Stott, Justen Manasa, et al.. (2014). Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges. BMC Health Services Research. 14(1). 116–116. 13 indexed citations

16.

Manasa, Justen, Richard Lessells, Theresa M. Rossouw, et al.. (2014). Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa. Database. 2014(0). bat082–bat082. 6 indexed citations

17.

Manasa, Justen, Richard Lessells, Andrew Skingsley, et al.. (2013). High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South Africa. PLoS ONE. 8(8). e72152–e72152. 49 indexed citations

18.

Ramagopalan, Sreeram V, Raph Goldacre, Andrew Skingsley, Chris Conlon, & Michael J Goldacre. (2013). Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Medicine. 11(1). 97–97. 44 indexed citations

19.

Handel, Adam E., et al.. (2012). Weekend admissions as an independent predictor of mortality: an analysis of Scottish hospital admissions. BMJ Open. 2(6). e001789–e001789. 44 indexed citations

20.

McGrath, Nuala, et al.. (2012). High levels of drug resistance after failure of first-line antiretroviral therapy in rural South Africa: impact on standardised second-line regimens. ePrints Soton (University of Southampton). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact